Form 8-K - Current report:
SEC Accession No. 0001517022-25-000030
Filing Date
2025-06-13
Accepted
2025-06-13 07:21:17
Documents
14
Period of Report
2025-06-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K akba-20250610.htm   iXBRL 8-K 47479
2 EX-99.1 ex9912023stockincentivepla.htm EX-99.1 128699
  Complete submission text file 0001517022-25-000030.txt   334473

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20250610.xsd EX-101.SCH 2139
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20250610_def.xml EX-101.DEF 3738
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20250610_lab.xml EX-101.LAB 25083
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20250610_pre.xml EX-101.PRE 14595
16 EXTRACTED XBRL INSTANCE DOCUMENT akba-20250610_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 251044740
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)